New Delhi: The Supreme Court Wednesday once again asked pharma company Novartis to scale down the price of its cancer drug Glivec, made from compound imatinib mesylate.The court suggested the price cut saying that the company`s scheme for providing the drug free to poor patients was complicated.The court said Tuesday: "Rs.1.2 lakh per month is too high to afford a treatment."Glivec is the trade name of chemical beta crystalline form of imatinib mesylate compound which is used for the treatment of chronic myeloid leukemia (CML) and malignant gastrointestinal stromal tumors.An apex court bench of Justice Aftab Alam and Justice Ranjana Prakash Desai told Novartis counsel Gopal Subramanium Wednesday that its proposal on poor patients was a "complicated scheme for identifying those who are entitled to be given (free medicine) and those who can afford paying 80 days of annual cost of Glivec".
Inflation woes: Prices of tomato, green chilli soar
Tutor caught torturing a 3-year-old on CCTV
Shiv Sena MPs `force` fasting Muslim to eat
Don`t take us for granted, NCP warns Congress